Matzku S, Brüggen J, Bröcker E B, Sorg C
Cancer Immunol Immunother. 1987;24(2):151-7. doi: 10.1007/BF00205593.
Immunohistology provides a necessary but insufficient criterion for selecting monoclonal antibodies (MAbs) capable of tumour targeting in vivo. Additional selection procedures have been evaluated using a panel of anti-melanoma MAbs, including immunoreactivity of (labelled) MAbs, antibody affinity, kinetics of binding and release, apparent antigen density and accumulation in nude mouse transplants. According to these criteria, MAbs M.2.7.6 and M.2.9.4 showed the most favourable properties, i.e. high immunoreactivity and pronounced internalization into melanoma cells. With MAbs M.2.10.15 and KG 6-56, moderate immunoreactivity and a binding pattern characterized by temperature dependence in the absence of internalization was observed. According to the paired label assay, all four MAbs showed specific accumulation into solid melanoma tissue. However, application in the patient still requires evaluation of the side effects of antigen cross-expression on normal human tissues.
免疫组织学为选择能够在体内靶向肿瘤的单克隆抗体（MAb）提供了一个必要但不充分的标准。已经使用一组抗黑色素瘤单克隆抗体评估了额外的选择程序，包括（标记的）单克隆抗体的免疫反应性、抗体亲和力、结合和释放动力学、表观抗原密度以及在裸鼠移植瘤中的积累。根据这些标准，单克隆抗体M.2.7.6和M.2.9.4表现出最有利的特性，即高免疫反应性和明显内化到黑色素瘤细胞中。对于单克隆抗体M.2.10.15和KG 6-56，观察到中等免疫反应性以及在没有内化的情况下以温度依赖性为特征的结合模式。根据配对标记分析，所有四种单克隆抗体都显示出在实体黑色素瘤组织中的特异性积累。然而，在患者中的应用仍需要评估抗原在正常人体组织上交叉表达的副作用。
